6.23

5.61% -0.37

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $6.23, with a volume of 1.96M. It is down -5.61% in the last 24 hours and up +41.27% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Previous Close:

$6.60

Open:

$6.67

24h Volume:

1.96M

Relative Volume:

2.42

Market Cap:

$368.17M

Revenue:

$192.64M

Net Income/Loss:

$2.51M

P/E Ratio:

118.89

EPS:

0.0524

Net Cash Flow:

$12.42M

1W Performance:

+15.58%

1M Performance:

+41.27%

6M Performance:

+34.56%

1Y Performance:

+34.85%

1-Day Range:

$6.15

$6.6957

1-Week Range:

$5.42

$6.88

52-Week Range:

$3.8092

$6.88

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

368

Twitter

Next Earnings Date

2025-05-02

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	6.23	390.04M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-25	Initiated	B. Riley Securities	Buy
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

Dec 11, 2025

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference - The AI Journal

Dec 11, 2025

Dec 08, 2025

FDA lifts partial clinical hold on Vanda Pharmaceuticals’ tradipitant - MSN

Dec 08, 2025

Dec 07, 2025